Parkside Financial Bank & Trust bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 339 shares of the company's stock, valued at approximately $50,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Signaturefd LLC boosted its holdings in shares of Medpace by 486.7% in the first quarter. Signaturefd LLC now owns 264 shares of the company's stock valued at $43,000 after acquiring an additional 219 shares in the last quarter. Lansing Street Advisors acquired a new stake in shares of Medpace in the first quarter valued at about $44,000. Prospera Financial Services Inc acquired a new stake in shares of Medpace in the first quarter valued at about $47,000. Meeder Asset Management Inc. acquired a new stake in shares of Medpace in the first quarter valued at about $121,000. Finally, Van ECK Associates Corp lifted its stake in shares of Medpace by 15.9% in the first quarter. Van ECK Associates Corp now owns 772 shares of the company's stock valued at $126,000 after purchasing an additional 106 shares during the period. Hedge funds and other institutional investors own 83.97% of the company's stock.

Medpace Trading Down 6.1 %

Shares of MEDP opened at $145.38 on Friday. The stock has a market cap of $4.51 billion, a P/E ratio of 25.24 and a beta of 1.47. The company has a 50-day moving average of $161.45 and a two-hundred day moving average of $152.75. Medpace Holdings, Inc. has a 12-month low of $126.94 and a 12-month high of $231.00.

Analyst Upgrades and Downgrades

Several analysts recently commented on MEDP shares. StockNews.com cut shares of Medpace from a "buy" rating to a "hold" rating in a research note on Thursday, September 8th. UBS Group started coverage on shares of Medpace in a research note on Wednesday, September 7th. They issued a "sell" rating and a $142.00 price objective for the company.

Insiders Place Their Bets

In other Medpace news, CEO August J. Troendle bought 22,290 shares of the business's stock in a transaction on Thursday, July 14th. The stock was bought at an average price of $144.59 per share, for a total transaction of $3,222,911.10. Following the completion of the transaction, the chief executive officer now owns 5,505,309 shares in the company, valued at approximately $796,012,628.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO August J. Troendle acquired 22,290 shares of the business's stock in a transaction dated Thursday, July 14th. The stock was acquired at an average price of $144.59 per share, with a total value of $3,222,911.10. Following the completion of the transaction, the chief executive officer now directly owns 5,505,309 shares in the company, valued at approximately $796,012,628.31. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Medpace Investors, Llc acquired 57,426 shares of the business's stock in a transaction dated Thursday, September 22nd. The stock was purchased at an average cost of $154.59 per share, with a total value of $8,877,485.34. Following the transaction, the insider now owns 6,483,019 shares of the company's stock, valued at $1,002,209,907.21. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 520,388 shares of company stock worth $81,752,898. Insiders own 20.60% of the company's stock.

About Medpace

(Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

Read More

• Get a free copy of the StockNews.com research report on Medpace (MEDP)
• MarketBeat: Week in Review 9/19 – 9/23
• Why Does Tesla Stock Remain Resilient?
• Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
• 2 Semiconductor Stocks To Watch For Reversals
• Will Crowdstrike Get A Boost From Increased EPS Guidance?

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.